Earlier intervention is expected to provide improved efficacy, and a study of ATG plus G-CSF combination therapy in new-onset T1D subjects will reach the primary endpoint in late 2017 (NCT02215200). Here, CSF3 is linked to type 1 diabetes mellitus.